Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 17, 2014, Pages 5031-5035

  Pallagi Kunstár, Éva ^a   Farkas, Klaudia ^a   Szepes, Zoltán ^a   Nagy, Ferenc ^a   Szucs, Mónika ^a   Kui, Róbert ^a   Gyulai, Roll ^a   Bálint, Anita ^a   Wittmann, Tibor ^a   Molnár, Tamás ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Antibody; Inflammatory bowel disease; Infliximab; Tumor necrosis factor a

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIBODY; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; DRUG HYPERSENSITIVITY; DRUG MONITORING; EVALUATION STUDY; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; PREDICTIVE VALUE; REMISSION; RISK FACTOR; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DRUG HYPERSENSITIVITY; DRUG MONITORING; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK FACTORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84899812340     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i17.5031     Document Type: Article

References (17)

1. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-1157 [PMID: 11040201]
2. Chaparro M, Guerra I, Muñoz-Linares P, Gisbert JP. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012; Epub ahead of print [PMID: 22443153 DOI: 10.1111/j.1365-2036.2012.05057.x]
3. Hanauer SB. Predicting, measuring, and maintaining response to TNF-α antagonists in inflammatory bowel disease. Adv Stud Med 2006; 6: 750-759
4. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608 [PMID: 12584368 DOI: 10.1056/ NEJMoa020888]
5. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-924 [PMID: 12671888 DOI: 10.1053/gast.2003.50145]
6. Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-752 [PMID: 16339288 DOI: 10.1136/ard.2005.045062]
7. Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006; 118: 11-19 [PMID: 16125467 DOI: 10.1016/ j.clim.2005.07.010]
8. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962 DOI: 10.1016/S0140-6736(02)08512-4]
9. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885 [PMID: 14985485 DOI: 10.1056/ NEJMoa030815]
10. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a metaanalysis. Am J Gastroenterol 2013; 108: 40-47; quiz 48 [PMID: 23147525 DOI: 10.1038/ajg.2012.363]
11. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-1254 [PMID: 16931170]
12. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54 [PMID: 19651627 DOI: 10.1136/gut.2009.183095]
13. Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 2010; 16: 1898-1904 [PMID: 20310016 DOI: 10.1002/ibd.21259]
14. Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 2013; 7: 736-743 [PMID: 23200919 DOI: 10.1016/j.crohns.2012.10.019]
15. Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-1139 [PMID: 20145610 DOI: 10.1038/ ajg.2010.9]
16. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70. e5; quiz e31 [PMID: 21945953 DOI: 10.1053/ j.gastro.2011.09.034]
17. Molnár T, Lakatos PL, Farkas K, Nagy F, Szepes Z, Miheller P, Horváth G, Papp M, Palatka K, Nyári T, Bálint A, Lo{double acute}rinczy K, Wittmann T. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013; 37: 225-233 [PMID: 23181359 DOI: 10.1111/apt.12160]